Table 1 a Household characteristics. b Characteristics of immunosuppressed children

From: Parental concern for clinically vulnerable child during first 18 months of the COVID pandemic

a

    
 

Full sample

Differential concern groups

Chi-square

p

  

Medium concern, full adaptation

Medium concern, some adaptation

High concern, some adaptation

High concern, no adaptation

  

Gender parent female N (%)

335 (89%)

60 (86%)

111 (87%)

122 (90%)

42 (95%)

5.02

0.54

Age parent median(range)

44 (27–62)

45 (27–59)

44 (30–58)

45 (27–62)

42 (32–56)

4.46**

0.22

Employment parent N (%)

     

21.65

0.001

 Fulltime

135 (36%)

26 (38%)

46 (37%)

53 (39%)

10 (23%)

  

 Parttime

159 (43%)

32 (47%)

62 (50%)

50 (37%)

15 (35%)

  

 Not working, disabled, retired

75 (20%)

10 (15%)

15 (12%)

32 (24%)

18 (42%)

  

Household composition N (%)

     

12.64

0.05

 Single parent w/child(ren)

51 (14%)

17 (24%)

13 (11%)

12 (9%)

9 (20%)

  

 Couple w/child(ren)

298 (80%)

48 (69%)

103 (84%)

115 (85%)

32 (73%)

  

 Couple w/child(ren) w/relatives

23 (6%)

5 (7%)

7 (6%)

8 (6%)

3 (7%)

  

Number of children median (range)

2 (1–12)

2 (1–5)

2 (1–5)

2 (1–12)

2 (1–3)

0.58

0.90

Household income N (%)

     

9.45

0.15

 >£29,500

236 (64%)

44 (65%)

85 (69%)

86 (64%)

21 (49%)

  

 ~£29,500

64 (17%)

9 (13%)

23 (19%)

23 (17%)

9 (21%)

  

 <£29,500

69 (19%)

15 (22%)

15 (12%)

26 (19%)

13 (30%)

  

Geography N (%)

 Scotland

51 (13%)

14 (19%)

16 (13%)

16 (12%)

5 (11%)

2.83

0.42

 Wales

15 (4%)

4 (6%)

2 (2%)

7 (5%)

2 (4%)

2.99*

0.31

 North England

90 (24%)

12 (17%)

30 (23%)

30 (22%)

18 (40%)

8.75

0.03

 Middle England

65 (17%)

12 (17%)

21 (16%)

24 (18%)

8 (18%)

0.11

0.99

 South England

159 (42%)

30 (42%)

59 (46%)

58 (43%)

12 (27%)

5.28

0.15

Urbanisation N (%)

     

6.80

0.34

 <2500 habitants

49 (13%

10 (14%)

20 (16%)

17 (13%)

2 (5%)

  

 2501–10,000 habitants

123 (33%)

17 (24%)

42 (33%)

46 (34%)

18 (41%)

  

 >10,000 habitants

202 (54%)

43 (61%)

64 (51%)

71 (53%)

23 (55%)

  

Access to green space N (%)

     

7.15

0.07

 Easy

354 (94%)

67 (96%)

124 (97%)

125 (93%)

38 (86%)

  

 (Somewhat) Difficult

23 (6%)

3 (4%)

4 (3%)

10 (7%)

6 (14%)

  

b

    
 

Full sample

Differential concern groups

Chi-square

p

  

Medium concern, full adaptation

Medium concern, some adaptation

High concern, some adaptation

High concern, no adaptation

  

Sample size (N)

765

153

262

257

93

  

Gender Female N (%)

408 (53%)

74 (48%)

144 (55%)

132 (51%)

58 (62%)

5.60

0.14

Age 10 + N (%)

419 (55%)

86 (56%)

150 (57%)

133 (52%)

50 (54%)

1.90

0.59

COVID-19 vaccination N (%)

160 (21%)

33 (22%)

55 (21%)

58 (23%)

14 (15%)

1.90

0.59

Diagnosis N (%)

 Gastroenterology

81 (11%)

11 (7%)

20 (8%)

40 (16%)

10 (11%)

11.00

0.01

 Nephrology

88 (12%)

16 (10%)

38 (15%)

26 (10%)

8 (9%)

3.70

0.29

 Solid organ transplant

27 (4%)

3 (2%)

6 (2%)

12 (5%)

6 (6%)

5.60*

0.14

 Diabetes

23 (3%)

3 (2%)

10 (4%)

9 (4%)

1 (1%)

2.57*

0.55

 Immune Deficient

81 (11%)

11 (7%)

36 (14%)

24 (9%)

10 (11%)

5.04

0.17

 Oncology

54 (7%)

15 (10%)

11 (4%)

23 (9%)

5 (5%)

6.82

0.08

 Respiratory

45 (6%)

10 (7%)

13 (5%)

17 (7%)

5 (5%)

0.81

0.84

 Juvenile Idiopathic Arthritis

282 (37%)

62 (41%)

97 (37%)

86 (33%)

37 (40%)

2.50

0.48

 Other immune

134 (18%)

28 (18%)

58 (22%)

37 (14%)

11 (12%)

7.75

0.05

 Other

188 (25%)

34 (22%)

59 (23%)

67 (26%)

28 (30%)

2.90

0.41

Medications N (%)

 Other drugsc

353 (46%)

70 (46%)

116 (44%)

123 (48%)

44 (47%)

0.73

0.87

 Chemotherapy

4 (1%)

1 (1%)

3 (1%)

0 (0%)

0 (0%)

3.84*

0.32

 Antibiotics

121 (16%)

20 (13%)

47 (18%)

39 (15%)

15 (16%)

1.84

0.61

 Other immune suppressants

166 (22%)

27 (18%)

57 (22%)

65 (25%)

17 (18%)

4.07

0.25

 Corticosteroids

152 (20%)

31 (20%)

49 (19%)

61 (24%)

11 (12%)

6.43

0.09

 Biologics

236 (31%)

56 (37%)

81 (31%)

74 (29%)

25 (27%)

3.57

0.31

 Methotrexate

216 (28%)

51 (33%)

67 (26%)

68 (26%)

30 (32%)

4.02

0.26

Location medical care N (%)

 South East

191 (25%)

40 (26%)

73 (28%)

54 (21%)

24 (26%)

3.47

0.33

 Southwest

25 (3%)

2 (1%)

6 (2%)

13 (5%)

4 (4%)

5.57

0.13

 East

48 (6%)

4 (3%)

11 (4%)

21 (8%)

12 (13%)

13.93

0.004

 East Midlands

47 (6%)

13 (8%)

14 (5%)

12 (5%)

8 (9%)

3.70

0.30

 West Midlands

142 (19%)

25 (16%)

49 (19%)

57 (22%)

11 (12%)

5.52

0.14

 Yorkshire and Humber

31 (4%)

11 (7%)

10 (4%)

10 (4%)

0 (0%)

7.86

0.03

 Northwest

87 (11%)

18 (12%)

36 (14%)

27 (11%)

6 (6%)

3.91

0.27

 Northeast

156 (20%)

31 (20%)

55 (21%)

51 (20%)

19 (20%)

0.11

0.99

 Wales

35 (5%)

8 (5%)

7 (3%)

12 (5%)

8 (9%)

5.78

0.12

  1. *Represents the P value of a Fisher exact test; **represents P value for Kruskal–Wallis statistic.
  2. cOther drugs include inhalers, eye drops, NSAIDs, folic acid, hypertonic saline, Omeprazole, insuline, hydrochloroquine, colchicine, antihypertensives, IViG, leflunomide, sulfasalazine, and mercaptopurine.
Back to article page